

Index

A

A1-antitrypsin deficiency, 47
Aberrations, identification of, 94–95
Abundance concept, 120
A-Catenin, 21
Acetaldehyde, 100
Acetylation, 3
Acute respiratory distress syndrome (ARDS), 161, 164
Adapter proteins, 36
Adenine (A)
 defined, 1
 in DNA structure, 109–111
Adult stem cells
 differentiation potential of, 148f, 149
 vs. embryonic stem cells, 148
 glossary of terms for, 148t
 injury response of, 149
 overview of, 147
Advanced sequencing, 66
Aflatoxins, 99
Age/aging, stem cells role in, 150
Alcohol/alcoholism, as carcinogen, 100
Alveolar lung tissue injury, 164
Amplicons
 detection of, 63–65
 lab design for, 67–68
 manufacture of, 75
 production techniques for, 62f
Amplification technologies
 with lasers, 91–92
 in PCR, 81f
 types of, 61–65
Anatomic pathology
 for infectious agents, 71
 for neoplasia, 70–71
 techniques in, 69
Animal models, 153–156
Annealing
 overview of, 73–75
 step programming for, 76
Antibodies
 for assessing biomarkers, 135
 monoclonal antibodies, 140
Antigens
 cell lineage-specific, 144t
 role in flow cytometry, 142–145
Apoptosis
 defined, 29
 inhibitors of, 36–37
 mechanisms of, 32–38

 types of, 30–32
Array technology
 bacterial artificial chromosome (BAC) arrays, 87–89
 in CGH, 116f
 large-insert clone arrays, 87–89
 nonredundant sequence arrays, 89
 oligonucleotide microarrays, 89–90
 repeat-free arrays, 89
Asbestos exposure
 loss of heterozygosity in, 99
 mesothelioma from, 156
Asthma
 animal model research in, 154
 loss of heterozygosity in, 103
Autophagy, 30–31
Autoschisis, 30f, 31–32

B

Baby hamster kidney(BHK) tissues, 169f
Background subtraction, 93
Bacteria
 Helicobacter pylori, 100
 Mycobacterium tuberculosis, 100
 Salmonella typhimurium, 177
Bacterial artificial chromosome (BAC) arrays, 87–89
Base excision repair (BER), 12
Base pairing, 109–111
B-Catenin, 21
B-cell lymphoma histogram, 143f
Bcl-2 family of proteins, 36, 37f
Benign diseases, loss of heterozygosity in, 102
Bioartificial muscle (BAM), 165
Bioinformatics, 55
Biomarker testing
 immunohistochemistry in, 133–134
 method standardization in, 134–135
Bioreactors, 164–165, 166, 168
Bladder cancer, loss of heterozygosity in, 99
Bleomycin installation, 154–155
Bone loss, 165–166
Bone marrow, 166
Bone marrow histogram, 143f
Bovine embryonic kidney (BEK) cells, 168
Branched chain DNA (bDNA), 65
BRCA genes, 100t
Breast cancer
 epimutations in, 48
 gene amplifications in, 43–44
 three-dimensional models of, 175

C

Cadherins

- cyclooxygenase 2 and, 21–22
- types and functions of, 20–22

Cancers/malignancies

- animal model research in, 153–156
- cell culture research in, 163
- chromosomal alterations in, 42
- common chromosomal deletions in, 43–44
- complex chromosomal rearrangements in, 44
- complex in cancer, 44
- epimutations in, 47–48
- gene amplifications in, 42–43
- gene mutations in, 45–46
- loss of heterozygosity in, 97, 100–103
- stem cell role in, 149–150
- See also specific cancers.*

Carcinogenesis

- from environmental factors, 99–100
- oncogenes role in, 70
- stem cells role in, 149–150

Carcinogens

- cigarette smoke. *See* Tobacco use.
- in foods, 99–100
- mutation mechanisms of, 99, 149–150

Carrel, Alexis, 159, 164–165

Caspases

- functions of, 33, 34f
- protein targets of, 37–38
- role in cell death, 32

CD44 adhesion molecule, 24

CD45 antigen

- in cell windows, 144f, 145
- overview of, 142
- vs. SSC, 143f
- windows/lineages in, 143f, 144

CDH13 gene, 100t

Cell adhesion molecules

- CD44 adhesion molecule, 24
- in cell culture, 162
- defined, 12
- role in cancer invasion, 19–24

Cell culture, primary

- biology of, 161–162
- cell adhesion in, 162
- defined, 160
- functional environments for, 162
- models for epithelial cultures, 162–163
- in study of disease processes, 161
- three-dimensional, 164–166

Cell cycle, 11–12

Cell death, alternative forms of, 29–32

Cell lines

- characteristics of, 160
- development of, 162

Cell populations

- basic parameters and windows of, 142–145
- for culture models, 162–163
- gating of, 142
- immunophenotyping analysis in, 142–144
- muscle cells, 165
- pulmonary alveolar type II cells, 164
- windows/lineages in, 143f, 144–145

CEP probes, 111–112

Charcot-Marie-Tooth disease (CMT), 45

Checkpoints (cell cycle), 11

Chlamydia pneumoniae, 100

Chondrocyte cultures, 169–171

Chromogenic in situ hybridization (CISH)

- defined, 69, 109
- vs. FISH, 115–116

Chromosomal alterations, diseases associated with, 42–45

Chromosomal deletions common in cancer, 43–44

Chromosomal microarrays, 66

Chromosomal paints, 112

Chromosomes

- cancer-specific LOH on, 100–103
- defined, 1

Chronic obstructive pulmonary disease (COPD)

- animal model research in, 153–155
- loss of heterozygosity in, 103

Cigarette smoke. *See* Tobacco use.

Cluster of differentiation (CD), 140

Codon, 2

Colon cancer, 174–175

Color blindness, 45

Colorectal cancer, epimutations in, 48

Comparative genomic hybridization (CGH), 69

- array platforms in, 87–90
- data analysis in, 93–95
- data smoothing in, 94
- facility setup for, 90
- image processing in, 93
- in loss of heterozygosity, 97
- normalization in, 93–94
- principle of, 87, 88f
- in situ type of, 116–117

Complementary DNA (cDNA) arrays, 87

Coomassie Brilliant Blue stains, 123

Cre recombinase, 155

Crotonaldehyde, 100

Culture media, 161–162

Cux-1 gene, 155

CXCR4 chemokine receptor, 20

Cyclooxygenase 2 (COX-2), 21–22

Cystic fibrosis (CF)

- animal model research in, 154
- overview of, 46–47

Cystic fibrosis transmembrane conductance regulator (CFTR),

47, 48, 154

Cytomegalovirus (CMV), 115f

Cytomics, 56

Cytosine (C)

- defined, 1
- in DNA structure, 109–111

Cytotoxic T cells, 35

D

Data analysis in CGH, 93–95

Data smoothing in CGH, 94

Data validation in proteomics, 121–122

Database searching for protein identification, 127–128

Dedifferentiation, 162

Denaturation

- defined, 111
- in FISH, 114
- overview of, 73–75
- step programming for, 76

Deoxynucleotides, 77

Deoxyribonucleic acid (DNA)

- amplification of, 91–92
- composition and structure of, 63f, 74f, 80f, 109, 110f
- damage repair for, 12

- defined, 1
- injected into mouse models, 153
- isolation and quality of, 90–91
- labeling of, 92
- melting temperature of, 111
- reference DNA, 92
- Desorption electrospray ionization (DESI) technique, 126
- Diaminobenzidine (DAB), 115
- Digestion, preparatory, enzymatic and nonenzymatic, 123
- Dimerization, 3
- Dimers, 3
- Direct labeled probes, 112
- Disease
 - animal model research in, 153–156
 - categories of, 41
 - cell culture's role in, 161
 - stem cell role in, 149–150
- DNA adducts, 99
- DNA chips, 62f
- Drug metabolism, 163
- Dual-probe real time PCR, 79–81

- E**
- E-Cadherin, 21
- Electrospray ionization (ESI), 125
- Embryonic stem cells
 - vs. adult stem cells, 148
 - differentiation potential of, 148f, 149
 - glossary of terms for, 148t
 - in knockout mouse models, 155–156
 - overview of, 147
- Emphysema, animal model research in, 154
- Enhancers, 4
- Environmental factors, carcinogenesis-related, 99–100
- Enzymatic preparatory digestion, 123
- Enzymes
 - caspsases. *See* Caspsases.
 - kinases. *See* Kinases.
 - polymerases. *See* Polymerase chain reaction (PCR).
 - for preparatory digestion, 123, 126
 - replication of, 2
 - Taq* polymerase, 73–75, 77, 79–81
 - See also specific enzymes.*
- Epidermal growth factor receptor (EGFR), 22, 71, 133
- Epimutations
 - defined, 41
 - diseases associated with, 47–48
- Epithelial cells, 162–163, 177–178
- Epithelial tissue, 177
- Epithelial-mesenchymal transition, 22
- Estrogen receptor positive [ER(+)] tumors, 133
- Euchromatin, 2
- Ex vivo propagation, 160
- Excision repair cross-complimentation group 1 (ERCC1), 133
- Extracellular pathway, 34f
- Extrinsic death pathway, functions of, 33, 35

- F**
- False discovery rate (FDR), 128
- False positives/false negatives in PCR, 71
- FHIT gene, 100t, 101
- Fibrosis, idiopathic, 154
- Field “cancerization”, 99
- Fingerprinting identification. *See* Protein mass fingerprinting identification.

- Fixation, incomplete, 135
- Flow cytometers, 140–141
- Flow cytometry
 - basic principles of, 139–140
 - compared to immunohistochemistry (IHC), 140t
 - data analysis and interpretation in, 142–145
 - overview of, 139
 - specimens suitable for, 141–142
 - technical aspects of, 140–142
- Fluorescence, 63–64
- Fluorescence in situ hybridization (FISH)
 - defined, 66, 109
 - multicolored, 117
 - specimens for, 113–114
 - steps involved in, 113–115
 - vs. CISH, 115–116
- Fluorescence microscopy for FISH, 114–115
- Fluorescence resonance energy transfer (FRET), 79–81
- Fluorescence-activated cell sorting (FACS), 147
- Fluorescent dyes, 140
- Fluorescent probes, 62f
- Fluorochromes, 140
- Focal adhesion kinase, 20
- Foods, carcinogens in, 99–100
- Formalin-fixed paraffin-embedded (FFPE) tissue, 69–71, 90, 135
- Forward light scatter (FSC), 142–145
- Fourier transform ion cyclotron resonance (FTICR), 125–126
- Fractional allelic loss (FAL), 98
- Fractionation, 120
- Free radicals, cancer-related, 100

- G**
- Gametes, 1
- Gastrointestinal epithelial cells, 163
- Gel electrophoresis
 - defined, 62f, 119
 - two dimensional. *See* Two-dimensional polyacrylamide gel electrophoresis (2D PAGE).
- Gene amplifications in cancers/malignancies, 42–43
- Gene expression
 - alterations of normal, 41–42
 - control of, 3
 - defined, 2
- Gene products
 - defined, 2
 - posttranslational modifications of, 3
- Gene sequencing, 62f, 65–66, 89, 127
- Genes
 - defined, 1
 - disease-specific genes, 155–156
 - splicing of, 129
 - tumor-specific genes, 100–101
 - See also* Proteins; Proteomics; *specific genes and procedures.*
- Genome, 1
- Genomics, 1, 55, 119
- Genotypes, 1–2
- GLUT-1 gene, 101
- Glycomics, 56
- GPX1 gene, 100t
- Granulocyte window, 145f
- Growth factor
 - receptors of, 9
 - signaling of, 11
- Guanine (G)
 - defined, 1
 - in DNA structure, 109–111

H

Helicobacter pylori, 100
 Hematopoietic stem cells, 147, 149
 Hepatocellular carcinoma (HCC), 100, 163
 Hepatocyte tissue cultures, 163
 HER2 gene, 116, 133, 136
 Hereditary nonpolyposis colon carcinoma (HNPCC), 134
 Heterochromatin, 2
 Heterodimers, 3
 Heterozygous status, 2
 Histograms
 of CD45 vs. SSC, 143f
 of FSC vs. SSC, 143f
 Histones, 1
 Homeostasis mechanisms, 149
 Homodimers, 3
 Homozygosity, 2, 97
 Hot start PCR, 78
 HRPT2 gene, 100t
 Human embryonic kidney (HEK) cells, 168
 Human leukocyte differentiation antigens (HLDA), 140
 Hybrid Capture, 65
 Hybridization probes/kinetics
 chromogenic in situ type of, 69, 109, 115–116
 defined, 111
 disadvantages in CGH, 92–93
 FISH vs. CISH, 115–116
 fluorescence in situ type of, 66, 69, 109, 114
 functions of, 62f, 63–64, 79, 80f
 general principles for in situ, 109–111
 overview of, 109
 Hydrolysis probes, 63–64

I

Idiopathic pulmonary fibrosis (IPF), 103
 Ig CAMS, 23–24
 Image processing in CGH, 93
 Imaging mass spectrometry (IMS), 124–127
 Immunophenotype cells, 140–141
 Immunodetection systems, 135–136
 Immunohistochemistry (IHC)
 in biomarker testing, 70, 133–136
 compared to flow cytometry, 140t
 Indirect labeled probes, 112
 Induced pluripotent stem cells (iPSCs), 150
 Infections
 cell culture research in, 163
 inflammation associated with, 100
 Infectious agents, anatomic pathology testing for, 71
 Inflammation associated with infections, 100
 Infrared multiphoton dissociation (IRMPD), 125–126
 Inhaled toxicants, 161
 In-house developed probes, 112
 Injury response of stem cells, 149
 Inner cell mass (ICM), 148f, 149
 Integrin-linked kinase (ILK), 20
 Integrins, 19–20
 Interstitial diseases, 154–155
 Interstitial pulmonary fibrosis (IPF), 154–155
 Intracellular pathway, 34f
 Intrinsic death pathway, 35–36
 Invader assays, 65
 Isoelectric focusing (IEF), 122

K

Karyotypes
 vs. CGH, 116–117
 defined, 1
 Kinases
 defined, 3
 integrin-linked, 20
 Knockout mouse models, 155–156
 KRAS gene, 70

L

Laboratory performance assessment, 136
 Laboratory staffing, 68
 Large-insert clone arrays, 87–89
 Ligands, 7
 LightCycler® PCR, 79, 81
 Liquid bead microarrays, 67
 Locus-specific probes, 112
 Loss of heterozygosity (LOH)
 chromosome- and tumor-specific, 100–103
 detection of, 97–99
 environmental influence on, 99–100
 gene- and tumor-specific, 100–103
 mechanisms of, 98f
 overview of, 97
 Lung cancer
 array CGH analysis of, 89f
 epimutations in, 47–48
 FISH detection of, 117f
 loss of heterozygosity in, 99
 ras mutations in, 45–46
 three-dimensional models of, 175
 Lung disease
 animal models of, 153–156
 three-dimensional models of, 172–174
 See also specific diseases.
 Lymphatic tissue culture, 163
 Lymphoblast window, 145f
 Lymphocyte window, 143–144
 Lymphokine activated killer (LAK) cells, 175–176

M

Magnesium in PCR, 77
 MASCOT database, 127–128
 Mass spectrometry
 defined, 62f, 67
 “dream team” system for, 125–126
 overview of, 123
 types of, 123–126
 Matrix-assisted laser desorption/ionization (MALDI), 123–124, 126–127
 Membrane bioreactors, 165
 Mesenchymal stem cells (MCSs), 149–150
 Mesothelioma
 animal model research in, 156
 loss of heterozygosity in, 99
 Messenger RNA (mRNA)
 defined, 2
 in reverse transcription, 81–83
 Metabolomics, 56
 Methylation
 defined, 47
 detection methods for, 66
 Methylation-specific PCR, 78

- Microarray technologies
 - defined, 56–57
 - types of, 66–67
- Microdissection (tissue)
 - defined, 69–70
 - with lasers, 91–92
- Mismatch repair genes (MMR), 12
- Missense mutations, 46
- Mitogen-activated protein kinase (MAPK), 9–10
- Mitosis, 11
- Molecular beacons, 63–64
- Molecular pathology/diagnostics
 - in anatomic pathology, 69–71
 - defined, 61, 62f
 - general approaches to, 61–68
 - lab design for, 67–68
- Molony murine leukemia virus (MMLV), 82
- Monocyte window, 145f
- Multicolor FISH (M-FISH), 117
- Multiple reaction monitoring (MRM), 130
- Multiplex PCR, 78–79
- Muscle cell growth, 165
- Mutations, genetic
 - defined, 41
 - diseases associated with, 45–47
 - missense and nonsense mutations, 42, 46
- Myc/Max/Mad network, 4
- Mycobacterial cultures, 71
- Mycobacterium tuberculosis*, 100
- Myeloblast window, 145f

- N**
- NASA Johnson Space Center, 172–174
- National Center for Biotechnology Information (NCBI), 127
- Necrosis, 29–30
- Neoplasia, testing for, 70–71. *See also* Cancers/malignancies.
- Nervous system tissue cultures, 163
- Nested PCR, 78
- Nitrosamines, 100
- Nonenzymatic preparatory digestion, 123
- Nonneoplastic diseases
 - chromosomal alterations in, 44–45
 - epimutations in, 48
 - gene mutations in, 46–47
- Nonredundant sequence arrays, 89
- Nonsense mutations, 42, 46
- Normal tissue models, 169–172, 175–178
- Normalization
 - algorithms for, 93
 - in CGH, 94
- Nucleic acid extraction, 61
- Nucleic acids, 1
- Nucleosomes, 1
- Nucleotide excision repair (NER), 12
- Nucleotide sequence alterations, 42
- Nucleotides, 1

- O**
- Oligodendroglial tumors, 100t, 101
- Oligonucleotide microarrays, 66, 89–90
- Omics
 - defined, 55
 - types of, 119–120
- Oncogene targeting, disease-specific, 155–156
- Oncogenes, 70
- Organ culture, 160
- Osteoporosis, 165–166
- Osteosarcoma, multicolor FISH of, 117f

- P**
- P53 tumor suppressor gene, 46
- Pancreatic cancer, 100
- Paraptosis, 30f, 31
- Pathogens, cancer-related, 100
- Peptides
 - heavy vs. light peptides, 129
 - sequencing of, 127
- Phenotypes, 1–2
- Phenylketonuria (PKU), 46–47
- Phenyx database, 127–128
- Phosphatases, 3
- Phosphorylation
 - defined, 3
 - process of, 9, 129
- Physiomics, 56
- Plasticity of stem cells, 149
- Polymerase chain reaction (PCR)
 - buffers in, 77
 - components of, 77
 - false positives/false negatives in, 71
 - procedure analysis of, 78–79
 - process of, 61–64
 - in real time, 63–64, 79–81
 - recent variations in, 78–79
 - setup for, 77–78
 - theory and principles of, 73–75
 - typical reagent mix for, 78t
- Polymerases, 2
- Posttranslational modifications, 129–130
- Prehybridization, 114
- Preparatory digestion, 123, 126
- Primary explants, 160, 164
- Primer design, 76–77
- Probes
 - preparation of, 112
 - types of, 111–112
 - See also* Hybridization probes/kinetics.
- Progenitor cells, 148f, 149
- Promoters, 4
- Promyelocytic leukemia (PML), 44
- Prostate carcinoma, 48, 175
- Proteases, 154
- Proteasomes, 3
- Protein Information Resource (PIR), 127
- Protein mass fingerprinting identification, 126–128
- Protein profiling, 120–121
- Proteins
 - complexes and interactions in, 130
 - degradation of, 3
 - identification of, 121, 126–128
 - quantification of, 128–129
 - staining of, 122–123
- Proteomics
 - defined, 56
 - as diagnostic hematology tool, 120
 - four methods of protein identification, 121
 - historical development of, 119–120
 - ideal proteomics, 120

- Proteomics (*cont.*)
 instrumentation for, 122–126
 protein staining in, 122–123
 proteomics pattern diagnostics, 125
 protocols for, 126–128
- Proto-tissues, 165
- Pulmonary alveolar type II cells, 164
- Pulmonary disease. *See* Lung disease.
- Pulmonary endothelial cells, 163
- Purines
 defined, 1
 in DNA structure, 109–111
- Pyrimidines
 defined, 1
 in DNA structure, 109–111
- Q**
- Quadrupole mass spectrometry, 125
- Quantification techniques, 129
- Quenching process, 80f
- R**
- Ras gene family, 45–46
- Real time sequencing, 65–66
- Receptors, cell surface, 9
- Reference DNA, 92
- RefSeq collection database, 127
- Renaturation, 111
- Repeat-free arrays, 89
- Replication, 2
- Representational oligonucleotide microarray analysis (ROMA), 92
- Restriction fragment length polymorphism (RFLP)
 defined, 65
 in loss of heterozygosity, 97
- Retinoblastoma (RB1) gene, 102
- Reverse transcription
 defined, 81–83
 reaction protocol for, 82f
- Ribonucleic acid (RNA)
 defined, 1
 in reverse transcription, 81–83
- Ribosomal RNA (rRNA), 2
- Rotating wall vessel (RWV)
 applications for, 166–172
 overview of, 173
 superior cells from, 176f
 tumor-specific models from, 174–175
- S**
- Salmonella typhimurium*, 177
- Sanger sequencing, 65
- Sarcoidosis, 103
- Satellite stem cells, 149
- Selectins, types and functions of, 22–24
- Sequencing. *See* Gene sequencing.
- Short tandem repeat (STR), 2–3
- Shotgun fractionation, 120
- Side light scatter (SSC), 142–145
- Signal amplification, 65
- Signaling pathways, 9
- Simian virus large T antigen (Tag), 155
- Single nucleotide polymorphisms (SNPs)
 defined, 2
 in loss of heterozygosity, 97–99
- Small cell lung cancer (SCLC), 101, 143f
- Smokeless tobacco
 as carcinogen, 99
See also Tobacco use.
- Sodium dodecyl sulfate (SDS) polyacrylamide gel, 122
- Sodium nitrate, 99–100
- Sodium nitrite, 99–100
- Southern blotting, 65
- Space bioscience, 165–166
- Spectra deconvolution, 121–122
- Spectral karyotyping (SKY), 69, 117
- Splicing, gene, 129
- Stem cells
 adult vs. embryonic, 147–148
 glossary of terms for, 148t
 overview of, 147
 plasticity of, 149
 role in pathogenesis, 149–150
- Surface-enhanced laser desorption/ionization mass spectrometry (SELDI), 124–125
- Surfactant protein C (SP-C), 155
- SV40 virus, 156
- Swiss-Prot database, 127
- Systems biology, 67
- T**
- Taq* polymerase, 73–75, 77, 79–81
- Target amplification, 61–65
- TATA-binding protein (TBP), 4
- Telomeres, 3
- Telomeric probes, 112
- Tetramers (four proteins), 3
- Thermocyclers, 75–76
- Thermostable polymerase, 77
- Three-dimensional biology
 examples of, 164–166
 study models for, 166–169
- Thymine (T)
 defined, 1
 in DNA structure, 109–111
- Time of flight (TOF) mass analyzer, 123–124, 126–127
- Tissue culture models
 2D vs. 3D, 177f
 advantages and limitations of, 160–161
 history of, 159
 types of, 160
- Tissue engineering stages, 167f, 172–174
- Tissue-like aggregates (TLAs), 175–178
- Tobacco use
 carcinogens associated with, 45–46
 COPD-related, 153
 in loss of heterozygosity, 99
- Topoisomerases, 2
- TP53 gene, 102
- Transcription
 defined, 2
 initiation of, 4
- Transcription factors, 3–4
- Transcription initiation site (TIS), 2
- Transcriptomics, 55, 119
- Transfer RNA (tRNA), 2
- Transgenic mouse models, 153–155
- Transgenic systems, 153–155

Translation

- defined, 2
 - posttranslational modifications, 129–130
- TrEMBL database, 127
- Trimers (three proteins), 3
- Trypsin, 123, 126
- Tumor necrosis factor receptor-2 (TNFR2), 101
- Tumor necrosis factor (TNF), 35
- Tumor suppressor genes (TSGs), 70–71
- Tumorigenesis. *See* Carcinogenesis.
- Tumors
- estrogen receptor positive [ER(+)], 133
 - stem cell role in, 149–150
- See also* Benign diseases; Cancers/malignancies.
- Two-dimensional polyacrylamide gel electrophoresis (2D PAGE), 122, 126–127
- Two-hit model, 97
- Type II pneumocytes, 164

U

- Ubiquitin, 3
- Ubiquitinylation, 3
- Unidirectional workflow, 68
- UniProt database, 127
- Uracil, 1

V

- Vacuolation, 30f, 31
- Validation process (protein match), 128
- Viral studies, 178
- Von Hippel-Lindau (VHL) gene, 100t

W

- Whole genome amplification (WGA), 91–92